Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
89
Views
9
Downloads
Abstract
among 292 nephrologists across India. A structured questionnaire provided to assess the efficacy and safety of Linagliptin in managing T2DM patients with renal impairment. The survey revealed strong endorsement from nephrologists for the efficacy and safety of Linagliptin. Among the nephrologists surveyed, a significant majority indicated that Linagliptin is highly effective in controlling blood glucose levels in T2DM patients with renal impairment. Additionally, nephrologists highlighted the safety profile of Linagliptin, noting its minimal renal excretion and low risk of hypoglycemia, making it particularly suitable for patients with varying degrees of renal function. The survey also found that Linagliptin is preferred over other glucose‐lowering agents due to its consistent efficacy and tolerability in patients with CKD and ESKD. Furthermore, nephrologists reported positive clinical outcomes, including improved glycemic control and stabilization of renal function, in patients treated with Linagliptin. The data underscores the broad consensus among nephrologists regarding Linagliptin as a first‐line treatment option for managing T2DM in the context of renal impairment. Linagliptin is the primary choice among nephrologists for managing T2DM in patients with renal impairment, indicating its significant role as a preferred therapeutic option in this patient population. This insight underscores the need for continued focus on Linagliptin in clinical practice and future research.
How to cite this article:
Sanjeev Gulati, Amol Mahaldar, Sanjiv Saxena, Ameet Rathod and Kunal Khobragade. Linagliptin in Managing Type 2 Diabetes with Renal Impairment: Insights from Indian Nephrologists.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.11.468.472
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.11.468.472